| Bioactivity | AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia[1]. | ||||||||||||
| Target | IC50: 38 nM (hLPA5). | ||||||||||||
| Name | AS2717638 | ||||||||||||
| CAS | 2148339-28-8 | ||||||||||||
| Formula | C25H25N3O5 | ||||||||||||
| Molar Mass | 447.48 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Murai N, et al. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents. Neuropharmacology. 2017 Nov;126:97-107. |